news
Viking Therapeutics announced positive initial results from a proof-of-concept study…
10 February 2017 | By Niamh Marriott (Drug Target Review)
Viking Therapeutics announced positive initial results from a proof-of-concept study of VK2809 in an in vivo model of glycogen storage disease Ia (GSD Ia).